Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of VX-828 Tablet vs Suspension in Healthy Adults
NCT06861413Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VX-828 in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Area Under the Concentration Versus Time Curve from the Time of dosing to the Last Measurable Concentration and Maximum Observed Concentration. Started Apr 2025; status: completed.
02
Drugs
VX-828
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06861413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861413.